Please forward and share with other faculty who may be interested.
Update on COVID-19 Vaccine Grant Support
With the recent U.S. Food and Drug Administration (FDA) emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine, in addition to previous authorizations in the U.K., Bahrain, Canada, Saudi Arabia and Mexico, there is an understandable interest from the healthcare community with how Pfizer will be supporting independent grants in this area. For more information on how Pfizer plans to support independent efforts in the areas of research, education and quality improvement with a primary goal of optimizing the prevention of COVID-19, please visit the COVID-19 VACCINE GRANTSpage.
Given the urgency and complexity of efforts required to respond to the global pandemic, Pfizer is launching their COVID-19 vaccine grant program in phases. Pfizer is currently accepting COVID-19 general research grant requests that address the following areas:
Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations
Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer’s vaccine particularly in specific patient populations
Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake
Please Note:
Currently, Pfizer is not accepting applications for clinical research that studies the safety, immunogenicity, and/or efficacy of Pfizer's COVID-19 vaccine.
To ensure vaccine availability for the general public, Pfizer is unable to provide COVID-19 vaccine as part of a grant.
If you have questions related to COVID-19 vaccine grants, please contact Derek Warnick, Grant Officer for Vaccines, at derek.warnick@pfizer.com.
Althea Sheets, Communications Manager, Office of Sponsored Programs, althea.sheets@unlv.edu, 702-895-1880
